Please login to the form below

Not currently logged in
Email:
Password:

The Sudler London Award for Excellence in Mature Brand Revitalisation

Sponsored by

Finalist

Making ERBITUX Matter: Born Fighters Campaign

Merck Serono in association with WCG


Summary of work

Merck Serono UK wanted to revitalise the perception of its personalised medicine ERBITUX to physicians treating patients with two types of cancer. ERBITUX was originally approved by the EMA in 2004 based on the pivotal CRYSTAL study results for colorectal cancer, and 2006 based on the pivotal BONNER study results for head and neck cancer. 

Seven years later, these studies are still the primary source of clinical evidence used to promote the use of ERBITUX in colorectal cancer and head and neck cancer. 

Because the colorectal indication requires the use of a biomarker and the head and neck cancer condition does not, the competition focused on convincing physicians it was the “easier” choice and positioned biomarker testing as a burden rather than a tool to guide treatment decisions which was inconsistently applied depending on indication. 

The creative approach across sales materials needed to be informative, compelling and consistent – while allowing for different indications – to facilitate physician dialogue beyond the traditional “data drone”. The result was “Born Fighters” – who represent all patients who deserve a fighting chance to defend their lives against cancer. 

 

 

Executive summary as submitted


COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...